Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

143 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Individualized treatment with combination of Peg-interferon alpha 2b and ribavirin in patients infected with HCV genotype 3.
Mangia A, Bandiera F, Montalto G, Mottola L, Piazzolla V, Minerva N, Pellicelli A, Ricci GL, Cela M, Carretta V, Scotto G, Bacca D, Annicchiarico B, Romano M, Russello M, Barbarini G, Agostinacchio E, Andriulli A. Mangia A, et al. Among authors: scotto g. J Hepatol. 2010 Dec;53(6):1000-5. doi: 10.1016/j.jhep.2010.04.042. Epub 2010 Aug 4. J Hepatol. 2010. PMID: 20843575 Clinical Trial.
Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3.
Mangia A, Santoro R, Minerva N, Ricci GL, Carretta V, Persico M, Vinelli F, Scotto G, Bacca D, Annese M, Romano M, Zechini F, Sogari F, Spirito F, Andriulli A. Mangia A, et al. Among authors: scotto g. N Engl J Med. 2005 Jun 23;352(25):2609-17. doi: 10.1056/NEJMoa042608. N Engl J Med. 2005. PMID: 15972867 Free article. Clinical Trial.
Determinants of relapse after a short (12 weeks) course of antiviral therapy and re-treatment efficacy of a prolonged course in patients with chronic hepatitis C virus genotype 2 or 3 infection.
Mangia A, Minerva N, Bacca D, Cozzolongo R, Agostinacchio E, Sogari F, Scotto G, Vinelli F, Ricci GL, Romano M, Carretta V, Petruzzellis D, Andriulli A. Mangia A, et al. Among authors: scotto g. Hepatology. 2009 Feb;49(2):358-63. doi: 10.1002/hep.22679. Hepatology. 2009. PMID: 19072829
Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial.
Barbaro G, Zechini F, Pellicelli AM, Francavilla R, Scotto G, Bacca D, Bruno M, Babudieri S, Annese M, Matarazzo F, Di Stefano G, Barbarini G; Lamivudine Italian Study Group Investigators. Barbaro G, et al. Among authors: scotto g. J Hepatol. 2001 Sep;35(3):406-11. doi: 10.1016/s0168-8278(01)00145-3. J Hepatol. 2001. PMID: 11592603 Clinical Trial.
Interferon alpha-2B and ribavirin in combination for patients with chronic hepatitis C who failed to respond to, or relapsed after, interferon alpha therapy: a randomized trial.
Barbaro G, Di Lorenzo G, Belloni G, Ferrari L, Paiano A, Del Poggio P, Bacca D, Fruttaldo L, Mongiò F, Francavilla R, Scotto G, Grisorio B, Calleri G, Annese M, Barelli A, Rocchetto P, Rizzo G, Gualandi G, Poltronieri I, Barbarini G. Barbaro G, et al. Among authors: scotto g. Am J Med. 1999 Aug;107(2):112-8. doi: 10.1016/s0002-9343(99)00160-6. Am J Med. 1999. PMID: 10460040 Clinical Trial.
Hepatitis C and immigration: a multicentre study.
Scotto G, Armignacco O, Starnini G, Francavilla R, Foti G, Portelli V, Mazzeo M, Minerva N, Carretta V, Lo Muzio L, Fazio V. Scotto G, et al. Infez Med. 2016 Sep 1;24(3):210-6. Infez Med. 2016. PMID: 27668901 Free article.
143 results